This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Soft tissue sarcoma of the extremity: Characterizing symptom duration and outcomes
Surg Oncol. 2019 Jun;29 :190-195
PMID: 31196487 URL: https://www.ncbi.nlm.nih.gov/pubmed/31196487
AbstractBACKGROUND: We sought to investigate how the interval between symptom onset and diagnosis of soft tissue sarcoma (STS) of the extremity was associated with survival. METHODS: Patients treated for extremity STS years 2006-2015 were stratified by symptom duration: at least two, six or twelve months between symptom onset and diagnosis. Chi-square tests compared patient and tumor-related characteristics based on symptom duration. Survival analysis included Cox regression and Kaplan-Meier estimates. RESULTS: Of 113 patients included, mean age was 56.7 years, 52.2% were male, and 75.2% were white. Median tumor size was 75mm, 48.7% were grade 3, and 38.1% were stage I. With symptom duration of either at least 6 or 12 months, a greater proportion of patients who experienced the specified symptom duration had lower grade tumors (p<0.01 and p=0.01, respectively) and lower stage disease (p<0.01 and p=0.02, respectively) than those who did not. Among all patients, survival estimates were similar between those who experienced a symptom duration of 2 (p=0.12), 6 (p=0.18) or 12 (p=0.61) months and those who did not. CONCLUSION: Patients with extremity STS who tolerated a longer symptom duration had less advanced disease. Reasons for prolonged symptom duration and methods to address these factors warrant further investigation.
Notes1879-3320 Moten, Ambria S Zhao, Huaqing Howell, Krisha Nadler, Ashlie Reddy, Sanjay S von Mehren, Margaret Movva, Sujana Farma, Jeffrey M Journal Article Netherlands Surg Oncol. 2019 Jun;29:190-195. doi: 10.1016/j.suronc.2019.05.016. Epub 2019 May 21.